{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BSX","limit":50},"count":50,"signals":[{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"performance, while the vesting period serves as a retention mechanism and encourages executives to maintain a long-term share ownership perspective.Time-based vesting: Vests in four equal annual installments, subject to continued service.Stockholder alignment: Provides executive ownership and directly aligns value with changes in our stock price. | | | | | | | Non-Qualified Stock OptionsNon-qualified","filed_date":"2026-03-18","accession":"0000885725-26-000025","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":35,"context":"RD VOTINGRECOMMENDATION | | | 1 | Elect to the Board of Directors ten nominees for director; | FOReach directornominee | | | | | 2 | Approve, on a non-binding, advisory basis, the compensation of our named executive officers; | FOR | | | | | 3 | Ratify the appointment of Ernst & Young LLP as our independent registered publicaccounting firm for the 2026 fiscal year; | FOR | | | | | | 4 | Approve an amendment to our Emplo","filed_date":"2026-03-18","accession":"0000885725-26-000025","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":21,"context":"itment of, and the Aggregate Multicurrency Outstandings held or deemed to be held by, any Defaulting Lender shall be excluded for purposes of making a determination of Majority Multicurrency Lenders. Material Adverse Effect a material adverse effect on (a) the business, operations, property or condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability o","filed_date":"2026-02-26","accession":"0000885725-26-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":34,"context":"t; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our co","filed_date":"2026-02-17","accession":"0000885725-26-000010","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":15,"context":"core businesses and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share,","filed_date":"2026-02-17","accession":"0000885725-26-000010","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":92,"context":"ovals and successfully manufacture and market our products consistent with our quality standards. If we fail to develop or acquire new products or enhance existing products, such failure could have a material adverse effect on our business, financial condition or results of operations. In addition, a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician con","filed_date":"2026-02-17","accession":"0000885725-26-000010","full_text":"https://origin.rootz.global/static/filing/0000885725-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":106,"context":"ty to own, lease and operate its properties and to carry on its business as it is now being conducted, except where the failure to be so validly existing and in good standing would not have a Company Material Adverse Effect. The Company is duly qualified or licensed as a foreign legal entity to do business, and is in good standing, in each jurisdiction where the character of the assets and properties owned, leased or op","filed_date":"2026-01-15","accession":"0000947871-26-000037","full_text":"https://origin.rootz.global/static/filing/0000947871-26-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":26,"context":"ay 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of","filed_date":"2025-11-03","accession":"0000885725-25-000050","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2025-11-03","accession":"0000885725-25-000050","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":27,"context":"ay 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of","filed_date":"2025-08-01","accession":"0000885725-25-000041","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2025-08-01","accession":"0000885725-25-000041","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":18,"context":"ay 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of","filed_date":"2025-05-01","accession":"0000885725-25-000026","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2025-05-01","accession":"0000885725-25-000026","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":29,"context":"RD VOTINGRECOMMENDATION | | | 1 | Elect to the Board of Directors ten nominees for director; | FOReach directornominee | | | | | 2 | Approve, on a non-binding, advisory basis, the compensation of our named executive officers; | FOR | | | | | 3 | Ratify the appointment of Ernst & Young LLP as our independent registered publicaccounting firm for the 2025 fiscal year; and | FOR | | | | | 4 | Stockholder proposal titled Sup","filed_date":"2025-03-19","accession":"0000885725-25-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":41,"context":"t; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve ESG goals; and future business decisions made by us and our competitors.","filed_date":"2025-02-18","accession":"0000885725-25-000011","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"core businesses and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share,","filed_date":"2025-02-18","accession":"0000885725-25-000011","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":95,"context":"hnology and operational technology systems that support our business operations and protect our data integrity and products from a cyber-attack, other breach or other malicious actors that may have a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/Ukraine war and conflicts in the Middle East.Innovation and Certain Growth I","filed_date":"2025-02-18","accession":"0000885725-25-000011","full_text":"https://origin.rootz.global/static/filing/0000885725-25-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":20,"context":"ay 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of","filed_date":"2024-11-01","accession":"0000885725-24-000073","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000073.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2024-11-01","accession":"0000885725-24-000073","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000073.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":20,"context":"ay 10, 2029, an amendment of the Ratings based pricing grid of the Applicable Margin, each as defined in the credit agreement, and reset the applicable date for purposes of determining the amounts of restructuring charges and restructuring-related expenses that may be excluded from consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined by the credit agreement, for purposes of","filed_date":"2024-08-01","accession":"0000885725-24-000068","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2024-08-01","accession":"0000885725-24-000068","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March31, 2024, we had $273 million of the restructuring charge exclusion remaining. In addition, any cas","filed_date":"2024-05-01","accession":"0000885725-24-000046","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets for a discuss","filed_date":"2024-05-01","accession":"0000885725-24-000046","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":40,"context":"D VOTINGRECOMMENDATION | | | 1 | Elect to the Board of Directors nine nominees for director; | FOReach directornominee | | | | | 2 | Approve, on a non-binding, advisory basis, the compensation of our named executive officers; | FOR | | | | | 3 | Approve an amendment and restatement of our By-Laws to provide for advance notice and universal proxy rule updates; and | FOR | | | | | 4 | Ratify the appointment of Ernst & You","filed_date":"2024-03-20","accession":"0000885725-24-000033","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":42,"context":"t; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future bu","filed_date":"2024-02-20","accession":"0000885725-24-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"core businesses and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share,","filed_date":"2024-02-20","accession":"0000885725-24-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":85,"context":"of patent litigation,Our ability to secure our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that may have a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war and Israel/Hamas war, andThe potential impact to internal contr","filed_date":"2024-02-20","accession":"0000885725-24-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":6,"context":"imited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023 and our acquisition of Baylis Medical Company Inc. (Baylis Medical) during the first quarter of 2022, for which there is less than a full peri","filed_date":"2024-02-20","accession":"0000885725-24-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":65,"context":"ty to own, lease and operate its properties and to carry on its business as it is now being conducted, except where the failure to be so validly existing and in good standing would not have a Company Material Adverse Effect. The Company is duly qualified or licensed as a foreign legal entity to do business, and is in good standing, in each jurisdiction where the character of the assets and properties owned, leased or op","filed_date":"2024-01-08","accession":"0000885725-24-000007","full_text":"https://origin.rootz.global/static/filing/0000885725-24-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":17,"context":"starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of September30, 2023, we had $369 million of the restructuring charge exclusion remaining. In addition","filed_date":"2023-11-01","accession":"0000885725-23-000048","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets","filed_date":"2023-11-01","accession":"0000885725-23-000048","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of June30, 2023, we had $416 million of the restructuring charge exclusion remaining. In addition, any","filed_date":"2023-08-03","accession":"0000885725-23-000043","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000043.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets","filed_date":"2023-08-03","accession":"0000885725-23-000043","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000043.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"starting date for purposes of calculating such permitted exclusions in each case from March 31, 2021 to December 31, 2022. Permitted exclusions include any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses associated with our current or future restructuring plans. As of March31, 2023, we had $457 million of the restructuring charge exclusion remaining. In addition, an","filed_date":"2023-05-04","accession":"0000885725-23-000026","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets","filed_date":"2023-05-04","accession":"0000885725-23-000026","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"rformance of our stock. The vesting period acts as a retention tool and promotes executives having a long-term share owner perspective.uFor awards granted in 2022, RSUs vest in four equal annual installments subject to continued serviceuService-based RSUs granted under programs prior to 2019 vested in five equal annual installmentsuPromote executive ownership and linkage to our share price | | | | |","filed_date":"2023-03-22","accession":"0000885725-23-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":54,"context":"ATION | | | | | 1 | Elect to the Board of Directors nine nominees for director | FOReach directornominee | | | | | | | | | | | | 2 | Approve, on a non-binding, advisory basis, the compensation of our named executive officers | FOR | | | | | | | | | | | | 3 | Approve, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of our named executive officers and | 1 YEAR | | | | | | | | |","filed_date":"2023-03-22","accession":"0000885725-23-000017","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":19,"context":"itment of, and the Aggregate Multicurrency Outstandings held or deemed to be held by, any Defaulting Lender shall be excluded for purposes of making a determination of Majority Multicurrency Lenders. Material Adverse Effect a material adverse effect on (a) the business, operations, property or condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability o","filed_date":"2023-03-01","accession":"0000885725-23-000010","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":54,"context":"olumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals and commitments; and future bu","filed_date":"2023-02-23","accession":"0000885725-23-000008","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":15,"context":"core franchises and pursue opportunities to diversify and further expand our presence in strategic, high-growth adjacencies and new global markets, including growth within the countries we define as emerging markets. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share,","filed_date":"2023-02-23","accession":"0000885725-23-000008","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":51,"context":"ent litigation, Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations including increased risks as an indirect result of the ongoing Russia/ Ukraine war, and The potential impact to internal control over financial re","filed_date":"2023-02-23","accession":"0000885725-23-000008","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":7,"context":"allocated to reportable segments, which are being disputed in the Italian court system. In 2021 and 2020, amounts relate to our Specialty Pharmaceuticals business. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Prior to the divestiture, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. Refer to Exe","filed_date":"2023-02-23","accession":"0000885725-23-000008","full_text":"https://origin.rootz.global/static/filing/0000885725-23-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of September30, 2022, we had $294 million of the restructuring charge exclusion remaining. In addition, any","filed_date":"2022-11-03","accession":"0000885725-22-000028","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"national | | | | | | | | | | 4 | | | | Specialty Pharmaceuticals | | | | | | | | | | 13 | | | | Total Net Sales | $ | 3,170 | | | $ | 2,932 | | | $ | 9,440 | | | $ | 8,761 | | | | | | | | | | | | | | Emerging Markets(1) | $ | 454 | | | $ | 354 | | | $ | 1,271 | | | $ | 1,031 | | | (1)We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, he","filed_date":"2022-11-03","accession":"0000885725-22-000028","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets","filed_date":"2022-11-03","accession":"0000885725-22-000028","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of June30, 2022, we had $311 million of the restructuring charge exclusion remaining. In addition, any cash","filed_date":"2022-08-04","accession":"0000885725-22-000023","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"platform_shift","strength":100,"match_count":13,"context":"national | | | | | | | | | | 4 | | | | Specialty Pharmaceuticals | | | | | | | | | | 13 | | | | Total Net Sales | $ | 3,244 | | | $ | 3,077 | | | $ | 6,270 | | | $ | 5,829 | | | | | | | | | | | | | | Emerging Markets(1) | $ | 427 | | | $ | 359 | | | $ | 817 | | | $ | 676 | | | (1)We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, health","filed_date":"2022-08-04","accession":"0000885725-22-000023","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B Acquisitions, Divestitures and Strategic Investments for a discussion of our strategic investments and Note C Goodwill and Other Intangible Assets","filed_date":"2022-08-04","accession":"0000885725-22-000023","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"including, without limitation, the authority to (i) construe, interpret, reconcile any inconsistency in, correct any default in and supply any omission in, and apply the terms of the Plan and any enrollment form or other instrument or agreement relating to the Plan, (ii) determine eligibility and adjudicate all disputed claims filed under the Plan, including whether Eligible Employees will participat","filed_date":"2022-05-06","accession":"0001104659-22-057017","full_text":"https://origin.rootz.global/static/filing/0001104659-22-057017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BSX","company":"BOSTON SCIENTIFIC CORP","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"financial covenant requirement provides for an exclusion from the calculation of consolidated EBITDA, as defined by the agreement, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of March31, 2022, we had $347 million of the restructuring charge exclusion remaining. In addition, any cas","filed_date":"2022-05-05","accession":"0000885725-22-000013","full_text":"https://origin.rootz.global/static/filing/0000885725-22-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"25e08e962b8172d586165bf1b079033e624b591259fe47ac6aec50ee39aa4d1f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"28e6521531082cd1745a47cf9cdf1bb8638cd162482177e5581d0a256b2ac9f2","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":54,"hourly_limit":500,"remaining":446,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}